Palatin to Report First Quarter Fiscal Year 2027 Results
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Palatin Technologies (Nasdaq: PTN) will announce its first quarter fiscal year 2027 operating results on November 17, 2026, before U.S. markets open.
The results release is scheduled for 7:30 a.m. ET. Executive management will host a conference call and live audio webcast at 11:00 a.m. ET that day, including an update on corporate and development activities. An audio webcast and replay will be available through the Investors-Webcasts section of Palatin's website.
Key Figures
- Results announcement
- November 17, 2026
- Q1 fiscal year 2027 results; before the U.S. market open
AI-generated analysis. How Rhea-AI works. Not financial advice.
Teleconference and Webcast to be held on November 17, 2026
Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 17, 2026, at 11:00 a.m. ET. The conference call will provide an update on corporate and development activities.
Schedule for the Operating Results Press Release, Conference Call / Audio Webcast
|
Q1 Fiscal Year 2027 Results Press Release |
11/17/2026 at 7:30 a.m. ET |
|
Q1 Fiscal Year 2027 Conference Call-Live |
11/17/2026 at 11:00 a.m. ET |
|
US Toll Free Dial-In Number: |
1-888-506-0062 |
|
International Dial-In Number: |
1-973-528-0011 |
|
Participant Access Code: |
336522 |
|
Q1 Fiscal Year 2027 Conference Call-Replay |
11/17/2026-12/01/2026 |
|
US Toll Free Dial-In Number: |
1-877-481-4010 |
|
International Dial-In Number: |
1-919-882-2331 |
|
Replay Passcode: |
54837 |
The audio webcast and replay can be accessed by logging on to the "Investors-Webcasts" section of Palatin's website at http://www.palatin.com or by clicking here.
About Palatin
Palatin Technologies, Inc. is a biopharmaceutical company developing medicines targeting the melanocortin receptor system. Palatin's principal strategic development focus is advancing next-generation MC4R-selective agonists for rare neuroendocrine obesity disorders, including hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome. The Company is developing long-acting injectable peptide agonists, oral small-molecule agonists and an oral peptide agonist approach, with the objective of delivering differentiated efficacy, tolerability and dosing profiles suitable for long-term treatment. Palatin also utilizes collaborations, licensing arrangements and strategic partnerships to advance other melanocortin-based programs. For more information, visit www.palatin.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-to-report-first-quarter-fiscal-year-2027-results-302938488.html
SOURCE Palatin Technologies, Inc.